Angle PLC Announces Agreement With Recursion Pharmaceuticals
Angle PLC Announces Agreement With Recursion Pharmaceuticals
New pharma agreement for Parsortix CTC analysis
Parsortix CTC分析的新制藥協議
GUILDFORD, SURREY / ACCESSWIRE / September 19, 2024 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce that it has signed an agreement with Recursion Pharmaceuticals, Inc. ("Recursion"), a leading clinical stage TechBio company decoding biology to radically improve lives.
吉爾福德，薩里 / ACCESSWIRE / 2024年9月19日 / ANGLE plc（AIM：AGL）（OTCQX：ANPCY），一家世界領先的液體活檢公司，提供用於研究、藥物研發和臨床腫瘤學的創新循環腫瘤細胞（CTC）解決方案，很高興宣佈與Recursion Pharmaceuticals, Inc.（以下簡稱"Recursion"）簽署協議，這是一家領先的臨床階段TechBio公司，通過解碼生物學來根本改善人們的生活。
The agreement is being initiated with a fully funded pilot study. Further details of the agreement are confidential between the parties.
這項協議由一項完全資助的試點研究發起。協議的詳細信息雙方之間保密。
ANGLE Chief Executive, Andrew Newland, commented:
"Whilst the study is modest in size during the pilot phase, there is the potential for larger follow-on contracts in the event of a successful pilot study. Recursion has partnerships with multiple leading large pharma companies and this agreement, ANGLE's fourth for 2024, further builds on the expansion of our large pharma services business."
ANGLE首席執行官安德魯·紐蘭特評論道：
"儘管在試點階段規模較小，但如果試點研究成功，可能會有更大型的後續合同。Recursion與多家領先的大型製藥公司有合作關係，而這項協議是ANGLE在2024年的第四個協議，進一步擴展了我們的大型製藥服務業務。"
For further information:
進一步了解：
ANGLE plc |
+44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
Berenberg (NOMAD and Broker) |
+44 (0) 20 3207 7800 |
FTI Consulting |
|
ANGLE plc |
+44（0）1483 343434 |
Andrew Newland，首席執行官 |
|
Berenberg（NOMAD和經紀人） |
+44（0）20 3207 7800 |
fti諮詢 |
|
For Frequently Used Terms, please see the Company's website on
有關常用術語，請參閱該公司網站，網址爲
Notes for editors
編輯註釋
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
關於ANGLE Plc
ANGLE是一家世界領先的液體活檢公司，擁有創新的循環腫瘤細胞（CTC）解決方案，可用於研究、藥物開發和臨床腫瘤學，使用簡單的血液樣本。ANGLE的經FDA批准並受專利保護的循環腫瘤細胞（CTC）收穫技術被稱爲Parsortix PC1系統，可以實現樣本的完整下游分析，包括整個細胞成像和蛋白質組分析，以及全基因組和轉錄組分子分析。
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
ANGLE的商業業務主要專注於診斷產品和臨床服務。診斷產品包括Parsortix系統、相關耗材和分析。臨床服務業務通過ANGLE的GCLP合規實驗室提供。服務包括定製分析開發和臨床試驗測試用於製藥。
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit
超過90篇同行評議的出版物證明了Parsortix系統的性能。 欲了解更多信息，請訪問
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit .
此信息由倫敦證券交易所的新聞發佈非監管分發服務Reach提供。可能適用於使用和分發此信息的條款和條件。如需更多信息，請聯繫rns@lseg.com或訪問。
SOURCE: ANGLE plc
來源：ANGLE plc
譯文內容由第三人軟體翻譯。
